HIV Drug Assistance Program (HDAP)

**PLEASE NOTE: For all COVID-19 updates regarding this program please visit**

The Massachusetts HIV Drug Assistance Program (HDAP) helps state residents who cannot afford to pay the full cost of the HIV-related drugs and health insurance they need.

HDAP is a program of the Office of HIV/AIDS within the Massachusetts Department of Public Health, funded through federal and state sources, including the U.S. Public Health Service/Health Resources and Services Administration and the Boston Public Health Commission AIDS Program through Part A of the Ryan White CARE Act.

HDAP is administered by Community Research Initiative and is among the nation’s most complete drug assistance programs for people living with HIV. It plays a crucial role in providing resources to a diverse population that may otherwise lack access to HIV-related medications and/or health insurance. More than half of HDAP enrollees are from communities of color, and approximately three-quarters of HDAP clients have incomes of less than 200 percent of the federal poverty level ($12,880).

HDAP can pay for:
•    medications and drug copays
•    private non-group health insurance premiums and drug copays
•    HIV-resistance testing (genotype and virtual phenotype lab tests)
•    post-exposure prophylaxis (PEP) for potential non-occupational exposure to HIV

For an overview of the HDAP/CHII programs, including eligibility requirements, please click here. More information is also available in our brochures:

**PLEASE NOTE: CRI is transitioning from its current model of pharmacy claims processing and payment to one utilizing an outside Pharmacy Benefits Manager (PBM) for all pharmacy claims adjudication for the Massachusetts HDAP and TBDAP programs. Currently, CRI processes claims internally for insured clients (i.e. co-pay claims) and externally through CVS Caremark for uninsured clients (i.e. full-pay claims). Beginning July 1, 2022 at 12:00 am EST, both full-pay and co-pay claims for eligible clients of HDAP and TBDAP will be processed by CRI’s new PBM vendor, Magellan Rx Management LLC (“MRx”) using its real-time adjudication system.

To read the full memo click here.**

Have you been exposed to HIV through a non-work-related event? Click here to learn about receiving antiretroviral treatment through HDAP’s Non-Occupational Post-Exposure Prophylaxis (nPEP) service.

Are you interested in preventing HIV by taking a once-daily pill? Click here to learn about PrEP and HDAP's PrEP Drug Assistance Program.